Painreform Ltd. (PRFX) has released an update.
PainReform Ltd. has announced positive results from their studies, showing that their non-opiate treatment PRF-110 outperforms leading competitors in post-surgical pain management. PRF-110 demonstrated higher analgesic drug release rates over both standard and extended testing durations, suggesting longer-lasting pain relief. These findings highlight the company’s commitment to providing safer and more effective pain management solutions, potentially reducing the reliance on opiates.
For further insights into PRFX stock, check out TipRanks’ Stock Analysis page.
